Modified mRNA for OTC Deficiency via Lipid Nanoparticle Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for ornithine transcarbamylase deficiency (OTCD) are limited, with no commercial therapeutics available and liver transplantation being the only curative option.

Innovation Solution

Development of a pharmaceutical composition comprising a polynucleotide encoding a human ornithine transcarbamylase (OTC) polypeptide, which is delivered via a lipid nanoparticle system to enhance protein expression and minimize immune activation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If liver transplantation is performed to cure OTCD, then curative effect is achieved, but treatment complexity and invasiveness increase significantly

Engineering Contradiction:

Improvecurative effectVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent replaces the mechanical surgical intervention of liver transplantation with a molecular-level therapeutic approach using modified mRNA molecules. The mRNA encodes functional OTC enzyme that is delivered directly to hepatocytes, allowing the cells to produce the missing enzyme without surgical removal or replacement of the liver organ.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces modified mRNA as an intermediary carrier that delivers the genetic information for OTC enzyme synthesis directly into liver cells. This mRNA intermediary acts as a bridge between the therapeutic goal (restoring OTC function) and the cellular machinery that produces proteins, avoiding the need for complex surgical transplantation procedures.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If conventional mRNA is used to encode OTC, then protein expression is achieved, but immune activation occurs

Engineering Contradiction:

Improveprotein expressionVSAvoidimmune activation

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent modifies specific parameters of the mRNA molecule, including the nucleotide sequence composition, 5' and 3' untranslated regions, and codon usage patterns. These parameter changes optimize the mRNA for efficient protein translation while simultaneously reducing its immunogenicity by avoiding recognition by host immune sensors.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent applies different quality characteristics to different regions of the mRNA molecule. The coding region is optimized for high-fidelity OTC protein expression, while the untranslated regions are specifically designed to minimize immune system recognition. This local optimization allows simultaneous achievement of high protein expression and low immune activation.

Inventive Principle:

Principle #3Local quality

Data Source

PatentEP3714048B1Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders

Publication Date: 2025.04.09 MODERNATX INC

Figure 1A
Figure 1B
Figure 1C

AI summary

This disclosure relates mRNA therapy for the treatment of ornithine transcarbamylase deficiency (OTCD). mRNAs for use in the invention, when administered in vivo, encode human ornithine transcarbamylase (OTC), isoforms thereof, functional fragments thereof, and fusion proteins comprising OTC. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of OTC expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic ammonia associated with deficient OTC activity in subjects.